Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Markman

Showing results (391-400 of 1,623) with videos related to

Pageof 163
Sort By:
Critical Reviews in Oncology/Hematology|February 1, 1993
Intraperitoneal therapy for treatment of malignant disease principally confined to the peritoneal cavityM Markman
Journal of Cancer Research and Clinical Oncology|January 1, 1996
Chemotherapy-associated neurotoxicity: an important side effect-impacting on quality, rather than quantity, of lifeM Markman
Oncology|December 7, 2016
Why Should Phase 1 Cancer Trial Participation and Optimal End-of-Life Care Be Incompatible?Maurie Markman
Expert Opinion on Drug Safety|August 9, 2003
Management of toxicities associated with the administration of taxanesMaurie Markman
Current Oncology Reports|June 5, 2003
Limitations to the use of the CA-125 antigen level in ovarian cancerMaurie Markman
Hematology/Oncology Clinics of North America|September 10, 2003
Optimizing primary chemotherapy in ovarian cancerMaurie Markman
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 14, 2003
The myth of measurable disease in ovarian cancerMaurie Markman
Current Oncology Reports|January 31, 2004
Duration of chemotherapy in low-versus high-volume metastatic cancer: should there be a difference?Maurie Markman
The Journal of Clinical Ethics|January 1, 1992
Ethical difficulties with randomized clinical trials involving cancer patients: examples from the field of gynecologic oncologyM Markman
Cleveland Clinic Journal of Medicine|December 23, 2003
The needs of science vs the needs of patients: ethical concerns in cancer clinical trialsMaurie Markman
Pageof 163

Showing results (391-400 of 1,623) with videos related to

Sort By:
Pageof 163
Critical Reviews in Oncology/Hematology|February 1, 1993
Intraperitoneal therapy for treatment of malignant disease principally confined to the peritoneal cavityM Markman
Journal of Cancer Research and Clinical Oncology|January 1, 1996
Chemotherapy-associated neurotoxicity: an important side effect-impacting on quality, rather than quantity, of lifeM Markman
Oncology|December 7, 2016
Why Should Phase 1 Cancer Trial Participation and Optimal End-of-Life Care Be Incompatible?Maurie Markman
Expert Opinion on Drug Safety|August 9, 2003
Management of toxicities associated with the administration of taxanesMaurie Markman
Current Oncology Reports|June 5, 2003
Limitations to the use of the CA-125 antigen level in ovarian cancerMaurie Markman
Hematology/Oncology Clinics of North America|September 10, 2003
Optimizing primary chemotherapy in ovarian cancerMaurie Markman
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 14, 2003
The myth of measurable disease in ovarian cancerMaurie Markman
Current Oncology Reports|January 31, 2004
Duration of chemotherapy in low-versus high-volume metastatic cancer: should there be a difference?Maurie Markman
The Journal of Clinical Ethics|January 1, 1992
Ethical difficulties with randomized clinical trials involving cancer patients: examples from the field of gynecologic oncologyM Markman
Cleveland Clinic Journal of Medicine|December 23, 2003
The needs of science vs the needs of patients: ethical concerns in cancer clinical trialsMaurie Markman
Pageof 163